| |  Online-Ressource |
|---|
| Verfasst von: | Klotz, Laura Valentina [VerfasserIn]  |
|---|
| | Zimmermann, Julia [VerfasserIn] |
|---|
| | Müller, Karolina [VerfasserIn] |
|---|
| | Kovács, Julia [VerfasserIn] |
|---|
| | Hassan, Mohamed [VerfasserIn] |
|---|
| | Koller, Michael [VerfasserIn] |
|---|
| | Schmid, Severin Thomas [VerfasserIn] |
|---|
| | Huppertz, Gunnar [VerfasserIn] |
|---|
| | Markowiak, Till [VerfasserIn] |
|---|
| | Passlick, Bernward [VerfasserIn] |
|---|
| | Hofmann, Hans-Stefan [VerfasserIn] |
|---|
| | Winter, Hauke [VerfasserIn] |
|---|
| | Hatz, Rudolf A. [VerfasserIn] |
|---|
| | Eichhorn, Martin E. [VerfasserIn] |
|---|
| | Ried, Michael [VerfasserIn] |
|---|
| Titel: | Multimodal treatment of pleural mesothelioma with cytoreductive surgery and hyperthermic intrathoracic chemotherapy |
|---|
| Titelzusatz: | impact of additive chemotherapy |
|---|
| Verf.angabe: | Laura V. Klotz, Julia Zimmermann, Karolina Müller, Julia Kovács, Mohamed Hassan, Michael Koller, Severin Schmid, Gunnar Huppertz, Till Markowiak, Bernward Passlick, Hans-Stefan Hofmann, Hauke Winter, Rudolf A. Hatz, Martin E. Eichhorn and Michael Ried |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 20 April 2024 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 15.01.2025 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 16(2024), 8, Artikel-ID 1587, Seite 1-13 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural mesothelioma (PM). The aim of this study was to evaluate the impacts of this multimodal approach in combination with systemic treatment on disease-free survival (DFS) and overall survival (OS). In this retrospective multicenter study, clinical data from patients after CRS and HITOC for PM at four high-volume thoracic surgery departments in Germany were analyzed. A total of 260 patients with MPM (220 epithelioid, 40 non-epithelioid) underwent CRS and HITOC as part of a multimodal treatment approach. HITOC was administered with cisplatin alone (58.5%) or cisplatin and doxorubicin (41.5%). In addition, 52.1% of patients received neoadjuvant and/or adjuvant chemotherapy. The median follow-up was 48 months (IQR = 38 to 58 months). In-hospital mortality was 3.5%. Both the resection status (macroscopic complete vs. incomplete resection) and histologic subtype (epithelioid vs. non-epithelioid) had significant impacts on DFS and OS. In addition, adjuvant chemotherapy (neoadjuvant/adjuvant) significantly increased DFS (p = 0.003). CRS and HITOC within a multimodal treatment approach had positive impacts on the survival of patients with epithelioid PM after macroscopic complete resection. The addition of chemotherapy significantly prolonged the time to tumor recurrence or progression. |
|---|
| DOI: | doi:10.3390/cancers16081587 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/cancers16081587 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/2072-6694/16/8/1587 |
|---|
| | DOI: https://doi.org/10.3390/cancers16081587 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | chemoperfusion |
|---|
| | cisplatin |
|---|
| | cytoreductive surgery |
|---|
| | decortication |
|---|
| | multimodal |
|---|
| | pleural mesothelioma |
|---|
| | thoracic surgery |
|---|
| K10plus-PPN: | 1914640519 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Multimodal treatment of pleural mesothelioma with cytoreductive surgery and hyperthermic intrathoracic chemotherapy / Klotz, Laura Valentina [VerfasserIn]; 20 April 2024 (Online-Ressource)
